
Semaglutide analysis links liver-risk subgroup to reduced cardiovascular events
A prespecified analysis of the SELECT trial found semaglutide reduced major adverse cardiovascular events in patients at elevated risk of substantial liver fibrosis while also lowering fatty liver index versus placebo.
- SELECT subgroup analysis focused on patients at elevated fibrosis risk.
- Semaglutide reduced major adverse cardiovascular events across reported fibrosis-risk definitions.






























































